振東製藥(300158.SZ):子公司與通遼政府就種植合作簽訂戰略合作框架協議
格隆匯1月20日丨振東製藥(300158.SZ)公佈,1月15日,公司下屬子公司山西振東道地藥材開發有限公司(“振東藥材”)與內蒙古自治區通遼市人民政府(“通遼政府”)就種植合作簽訂了《戰略合作框架協議》。
據悉,內蒙古通遼市是中國乃至國際蒙藥的重要發源地,2016年被命名為“中國蒙醫藥之都”,蒙醫整骨術被列入“國家非物質文化遺產”名錄。國內最大的蒙藥生產基地、蒙藥材種植基地、國內最早成立的蒙藥廠、全國最大的蒙藥貼生產基地都在通遼市,中醫藥(蒙醫藥)產業是通遼市的特色產業之一。
公吿稱,振東藥材與通遼政府簽署《戰略合作框架協議》將充分發揮各自優勢,資源互補,提高公司品牌知名度和中藥材銷售,促進通遼市中(蒙)醫藥的發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.